SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
17.30
-0.10 (-0.57%)
Apr 14, 2026, 5:29 PM CET
Market Cap974.43M +30.4%
Revenue (ttm)n/a
Net Income-110.83M
EPS-2.17
Shares Out56.00M
PE Ration/a
Forward PE17.06
Dividendn/a
Ex-Dividend Daten/a
Volume278,303
Average Volume205,697
Open17.46
Previous Close17.40
Day's Range16.90 - 17.70
52-Week Range13.40 - 25.30
Beta0.99
RSI44.32
Earnings DateApr 15, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements